Cancer Biomarkers Market By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Epigenetic Biomarkers), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Blood Cancers, Others), By Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Immunoassays, Next-Generation Sequencing, PCR-based Techniques), By Application (Diagnostics, Prognostics, Risk Assessment, Therapy Prediction/Monitoring, Companion Diagnostics), By End-user (Hospitals, Cancer Research Institutes, Diagnostic Laboratories, Biopharmaceutical and Biotechnology Companies, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methdology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cancer Biomarkers Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. The rising global cancer incidence demands early detection and targeted treatment solutions.

3.2.2. Advancements in genomics, proteomics, and liquid biopsy technologies are driving diagnostic accuracy.

3.2.3. Increased investment and government support for cancer biomarker research and precision medicine.

3.3. Key industry pitfalls & challenges

3.3.1. The prohibitive cost of biomarker-based diagnostics limits accessibility in low-income regions.

3.3.2. Complexity in validation and regulatory approval of new biomarker tests.

3.3.3. Limited awareness and infrastructure for biomarker testing in developing countries.

3.4. Market Opportunities

3.4.1. Growing demand for personalized medicine and companion diagnostics in oncology care.

3.4.2. Technological innovations in AI and big data analytics enhancing biomarker discovery.

3.4.3. Expansion of biomarker applications into immunotherapy and minimal residual disease monitoring.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cancer Biomarkers Market, Biomarker Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Biomarker Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Genetic Biomarkers

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Protein Biomarkers

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Metabolic Biomarkers

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Epigenetic Biomarkers

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Cancer Biomarkers Market, Cancer Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Cancer Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Breast Cancer

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Lung Cancer

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Colorectal Cancer

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Prostate Cancer

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Melanoma

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Blood Cancer

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Others

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Cancer Biomarkers Market, Technology Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Technology, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Omics Technologies

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Imaging Technologies

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Bioinformatics

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Immunoassays

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Next-Generation Sequencing

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. PCR-based Techniques

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Cancer Biomarkers Market, Application Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Application, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Diagnostics

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Prognostics

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Risk Assessment

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Therapy Monitoring

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Companion Diagnostics

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.7. Others

7.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Cancer Biomarkers Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Cancer Research Institutes

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Diagnostic Laboratories

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Biopharmaceutical and Biotechnology Companies

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.6. Others

8.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Cancer Biomarkers Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Biomarker Type, 2025-2035

9.2.3. North America Market Revenue, By Cancer Type, 2025-2035

9.2.4. North America Market Revenue, By Technology, 2025-2035

9.2.5. North America Market Revenue, By Application, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Biomarker Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Cancer Type, 2025-2035

9.2.7.3. U.S. Market Revenue, By Technology, 2025-2035

9.2.7.4. U.S. Market Revenue, By Application, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Biomarker Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Cancer Type, 2025-2035

9.2.8.3. Canada Market Revenue, By Technology, 2025-2035

9.2.8.4. Canada Market Revenue, By Application, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Biomarker Type, 2025-2035

9.3.3. Europe Market Revenue, By Cancer Type, 2025-2035

9.3.4. Europe Market Revenue, By Technology, 2025-2035

9.3.5. Europe Market Revenue, By Application, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Biomarker Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Cancer Type, 2025-2035

9.3.7.3. Germany Market Revenue, By Technology, 2025-2035

9.3.7.4. Germany Market Revenue, By Application, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Biomarker Type, 2025-2035

9.3.8.2. France Market Revenue, By Cancer Type, 2025-2035

9.3.8.3. France Market Revenue, By Technology, 2025-2035

9.3.8.4. France Market Revenue, By Application, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Biomarker Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Cancer Type, 2025-2035

9.3.9.3. U.K. Market Revenue, By Technology, 2025-2035

9.3.9.4. U.K. Market Revenue, By Application, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Biomarker Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Cancer Type, 2025-2035

9.3.10.3. Italy Market Revenue, By Technology, 2025-2035

9.3.10.4. Italy Market Revenue, By Application, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Biomarker Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Cancer Type, 2025-2035

9.3.11.3. Spain Market Revenue, By Technology, 2025-2035

9.3.11.4. Spain Market Revenue, By Application, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Biomarker Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Cancer Type, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Technology, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Application, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Biomarker Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Application, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Biomarker Type, 2025-2035

9.4.7.2. China Market Revenue, By Cancer Type, 2025-2035

9.4.7.3. China Market Revenue, By Technology, 2025-2035

9.4.7.4. China Market Revenue, By Application, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Biomarker Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Cancer Type, 2025-2035

9.4.8.3. Japan Market Revenue, By Technology, 2025-2035

9.4.8.4. Japan Market Revenue, By Application, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Biomarker Type, 2025-2035

9.4.9.2. India Market Revenue, By Cancer Type, 2025-2035

9.4.9.3. India Market Revenue, By Technology, 2025-2035

9.4.9.4. India Market Revenue, By Application, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Biomarker Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Cancer Type, 2025-2035

9.4.10.3. Australia Market Revenue, By Technology, 2025-2035

9.4.10.4. Australia Market Revenue, By Application, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Biomarker Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Cancer Type, 2025-2035

9.4.11.3. South Korea Market Revenue, By Technology, 2025-2035

9.4.11.4. South Korea Market Revenue, By Application, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Biomarker Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Cancer Type, 2025-2035

9.4.12.3. Singapore Market Revenue, By Technology, 2025-2035

9.4.12.4. Singapore Market Revenue, By Application, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Biomarker Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Cancer Type, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Technology, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Application, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Biomarker Type, 2025-2035

9.5.3. Latin America Market Revenue, By Cancer Type, 2025-2035

9.5.4. Latin America Market Revenue, By Technology, 2025-2035

9.5.5. Latin America Market Revenue, By Application, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Biomarker Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Cancer Type, 2025-2035

9.5.7.3. Brazil Market Revenue, By Technology, 2025-2035

9.5.7.4. Brazil Market Revenue, By Application, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Biomarker Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Cancer Type, 2025-2035

9.5.8.3. Argentina Market Revenue, By Technology, 2025-2035

9.5.8.4. Argentina Market Revenue, By Application, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Biomarker Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Cancer Type, 2025-2035

9.5.9.3. Mexico Market Revenue, By Technology, 2025-2035

9.5.9.4. Mexico Market Revenue, By Application, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Biomarker Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Cancer Type, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Technology, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Application, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Biomarker Type, 2025-2035

9.6.3. MEA Market Revenue, By Cancer Type, 2025-2035

9.6.4. MEA Market Revenue, By Technology, 2025-2035

9.6.5. MEA Market Revenue, By Application, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Biomarker Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Cancer Type, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Technology, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Application, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Biomarker Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Cancer Type, 2025-2035

9.6.8.3. South Africa Market Revenue, By Technology, 2025-2035

9.6.8.4. South Africa Market Revenue, By Application, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Biomarker Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Cancer Type, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Technology, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Application, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. F. Hoffmann-La Roche Ltd.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product/Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Thermo Fisher Scientific Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product/Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.2.6. Business Overview

10.2.7. Financial Performance

10.2.8. Product/Service Offerings

10.2.9. Strategies & recent developments

10.2.10. SWOT Analysis

10.3. Illumina, Inc.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product/Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. QIAGEN N.V.

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product/Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Bio-Rad Laboratories, Inc.

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product/Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. Abbott Laboratories

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product/Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Bristol Myers Squibb

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product/Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Agilent Technologies, Inc.

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product/Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Becton, Dickinson and Company (BD)

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product/Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. Myriad Genetics, Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product/Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Sysmex Corporation

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product/Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Genomic Health

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product/Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. PerkinElmer, Inc.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product/Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Guardant Health, Inc.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product/Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Foundation Medicine, Inc.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product/Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis